Nektar Therapeutics’ (NKTR) “Market Perform” Rating Reaffirmed at William Blair
William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...
Nektar completes enrollment in REZOLVE-AA Phase 2b trial of rezpegaldesleukin
Therapeutics announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...
William Blair Keeps Their Hold Rating on Lantheus (LNTH)
William Blair analyst Andy Hsieh reiterated a Hold rating on Lantheus (LNTH – Research Report) today. The company’s shares opened today at ...
JD Supra2h
Key Health Care Issues to Track in 2025 in Alabama
This update examines the shifting landscape of healthcare regulation and industry developments in Alabama. It addresses key areas ...